After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In this course students will implement and test advanced data structures and algorithms, benchmark performance, analyze algorithmic complexity, explore trade offs in performance and memory usage, and ...

The USPS is investing in advanced package sorting machines like the PILS and MEWS to increase efficiency and reduce costs, as part of a larger 10-year, $40 billion modernization plan. The PILS system ...

All right. Fantastic. We will go ahead and kick it off day 2 of the Goldman Sachs Communacopia + Technology Conference. Thanks so much, everyone, for joining us at the CrowdStrike session. Delighted ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...